Clinical and laboratory phenotype associated with the aspirin-like defect.


Ayliffe, M.J., Davies, F.E., de Castro, D. & Morgan, G.J. (2007) Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica, 92, 1135–1138. Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. & Drew, R. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673–680. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875–1883. Dawson, M.A., Patil, S. & Spencer, A. (2007) Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica, 92, 143–144. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467–1473. Hobbs, J.R. (1969) Growth rates and responses to treatment in human myelomatosis. British Journal of Haematology, 16, 607–617. Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. & Dimopoulos, M.A. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 1351–1358. Kühnemund, A., Liebisch, P., Bauchmüller, K., Zur Hausen, A., Veelken, H., Wäsch, R. & Engelhardt, M. (2009) ‘Light-chain escapemultiple myeloma’ – an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. Journal of Cancer Research and Clinical Oncology, 135, 477–484. Wechalekar, A.D., Goodman, H.J.B., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2007) Safety and efficacy of riskadapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457–464.

DOI: 10.1111/j.1365-2141.2009.07950.x

Cite this paper

@article{Dragani2010ClinicalAL, title={Clinical and laboratory phenotype associated with the aspirin-like defect.}, author={Alfredo Dragani and Francesco Brancati and Silvia Pascale and Domenico Mattoscio and Bianca Rocca}, journal={British journal of haematology}, year={2010}, volume={148 4}, pages={661-3; author reply 663-4} }